J Med Microbiol International Journal of Systematic and Evolutionary Microbiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Capoor, M. R.
Right arrow Articles by Pillai, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Capoor, M. R.
Right arrow Articles by Pillai, P.
Agricola
Right arrow Articles by Capoor, M. R.
Right arrow Articles by Pillai, P.
J Med Microbiol 58 (2009), 337-341; DOI: 10.1099/jmm.0.47853-0
© 2009 Society for General Microbiology
ISSN 0022-2615

Minimum inhibitory concentration of carbapenems and tigecycline against Salmonella spp.

Malini R. Capoor1, Deepthi Nair1, Jitendra Posti1, Smita Singhal2, Monorama Deb1, Pushpa Aggarwal1 and Parukutty Pillai3

1 Department of Microbiology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India

2 New Drug Discovery, Ranbaxy Research Laboratories, Gurgaon, India

3 Department of Microbiology, Majeedia Hospital, Hamdard University, New Delhi, India

Correspondence
Deepthi Nair
deepthinair2{at}gmail.com

Received December 31, 2007
Accepted October 31, 2008

Antimicrobial resistance in Salmonella spp. is of grave concern, more so in quinolone-resistant and extended-spectrum β-lactamase (ESBL)-producing isolates that cause complicated infections. The MIC of azithromycin, ciprofloxacin, cefixime, cefepime, ceftriaxone, gatifloxacin, imipenem, levofloxacin, meropenem and ofloxacin (E-test strip) and tigecycline and faropenem (agar dilution) against 210 Salmonella spp. was determined. MIC90 (defined as the antimicrobial concentration that inhibited growth of 90 % of the strains) of the carbapenems (imipenem and meropenem) for Salmonella Typhi and Salmonella Paratyphi A was 0.064 µg ml–1. MIC90 of faropenem was 0.25 µg ml–1 for S. Typhi, S. Paratyphi A and Salmonella Typhimurium. The MIC90 of azithromycin for all Salmonella spp. ranged from 8 to 16 µg ml–1. Tigecycline showed an MIC90 of 2 µg ml–1 for S. Typhi, 1 µg ml–1 for S. Paratyphi A and 4 µg ml–1 for S. Typhimurium. We concluded that tigecycline and the carbapenems are likely to have roles in the final stage of treatment of quinolone-resistant and ESBL-producing multidrug-resistant salmonellae.

Abbreviations: CLSI, Clinical and Laboratory Standards Institute; ESBL, extended-spectrum β-lactamase; EUCAST, European committee on antimicrobial susceptibility testing; FDA, Food and Drug Administration; MDR, multidrug-resistant; MIC50 and MIC90, antimicrobial concentration that inhibited growth of 50 and 90 %, respectively, of the strains; NAR, nalidixic acid-resistant.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 2009 Society for General Microbiology.